On this page

Sodium Acetate

Prescription ANDA TE AP Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Sodium Acetate
Generic name
Sodium Acetate
Dosage form
Injection
Route
Intravenous
Marketing category
ANDA · ANDA
Labeler
Hikma Pharmaceuticals USA Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
3
Packages
3
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Sodium Acetate Anhydrous 164 mg/mL 801451 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Injection
Route of administration
Intravenous
Presentations
6

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Increased Large Intestinal Motility [PE] PE All 83 members
Inhibition Large Intestine Fluid/Electrolyte Absorption [PE] PE All 83 members
Osmotic Activity [MoA] MoA All 105 members
Osmotic Laxative [EPC] EPC All 103 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
216920
Application type
ANDA · Abbreviated New Drug Application
Approval date
March 15, 2024
Sponsor
HIKMA
Products on application
3
Submissions recorded
1
Products approved under application 216920.
Product Trade name Form Strength Ingredient Status TE Flags
216920-001 SODIUM ACETATE SOLUTION SODIUM ACETATE Prescription AP
216920-002 SODIUM ACETATE SOLUTION SODIUM ACETATE Prescription AP
216920-003 SODIUM ACETATE SOLUTION SODIUM ACETATE Prescription AP

Therapeutic equivalence

Source: Orange Book
TE code
AP
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (parenteral aqueous solutions)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 216920.
Type No. Action Status Date Review
Original application 1 Approved March 15, 2024 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20240508). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20240508

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Sodium acetate injection (2 mEq/mL) is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Sodium acetate injection (2 mEq/mL) is administered intravenously only after dilution in a larger volume of fluid . The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium should be monitored as a guide to dosage. Using aseptic technique, transfer the desired amount to other intravenous fluids to provide the appropriate number of milliequivalents (mEq) of sodium acetate. Sodium acetate injection (2 mEq/mL) in the Pharmacy Bulk Package is designed for use with manual, gravity flow operations and automated compounding devices for preparing intravenous nutritional admixtures. Admixtures must be stored under refrigeration and used within 24 hours after compounding. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. (see PRECAUTIONS ). Directions for Dispensing From Pharmacy Bulk Package The Pharmacy Bulk Package is for use in the Pharmacy Admixtures Service only. For hanger application, peel off the paper liner from both ends of the tape hanger to expose 3⁄4 inch long adhesive portions. Adhere each end to the label on the bottle. The vials should be suspended as a unit in the laminar flow hood. A single entry through the vial closure should be made with a sterile dispensing set or transfer device. Transfer individual doses to appropriate intravenous infusion solutions. Use of a syringe with needle is not recommended as it may cause leakage and multiple entries will increase the potential of microbial and particulate contamination. The above process should be carried out under a laminar flow hood using aseptic technique. Discard any unused portion within 4 hours after initial closure entry.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Sodium acetate injection (2 mEq/mL) is contraindicated in patients with hypernatremia or fluid retention.

WARNINGS Sodium acetate injection (2 mEq/mL) must be diluted before use. To avoid sodium overload and water retention, infuse sodium-containing solutions slowly. Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. Solutions containing acetate ions should be used with great care in patients with metabolic or respiratory alkalosis. Acetate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency. The intravenous administration of this solution (after appropriate dilution) can cause fluid and/or solute overloading resulting in dilution of other serum electrolyte concentrations, overhydration, congested states or pulmonary edema. Excessive administration of potassium free solutions may result in significant hypokalemia. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Sodium overload can occur with intravenous infusion of excessive amounts of sodium- containing solutions. (see WARNINGS and PRECAUTIONS ).

Description

openFDA Drug Labeling

DESCRIPTION Sodium acetate injection USP, (2 mEq/mL) is a sterile, nonpyrogenic, concentrated solution of sodium acetate in water for injection. The solution is administered after dilution by the intravenous route as an electrolyte replenisher. It must not be administered undiluted. Each mL contains 164 mg of sodium acetate (anhydrous) which provides 2 mEq each of sodium (Na + ) and acetate (CH 3 COO - ). The solution contains no bacteriostat, antimicrobial agent or added buffer. May contain acetic acid for pH adjustment; the pH is 6.5 (6.0 to 7.0). The osmolar concentration is 4 mOsmol/mL (calc.); specific gravity 1.081. The solution is intended as an alternative to sodium chloride to provide sodium ion (Na + ) for addition to large volume infusion fluids for intravenous use. Sodium Acetate, USP anhydrous is chemically designated CH 3 COONa, a hygroscopic powder very soluble in water. A Pharmacy Bulk Package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion.

OVERDOSAGE In the event of overdosage, discontinue infusion containing sodium acetate immediately and institute corrective therapy as indicated to reduce elevated serum sodium levels, and restore acid- base balance if necessary. (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Sodium acetate injection USP, (2 mEq/mL) is supplied in Pharmacy Bulk Packages as follows: Unit of Sale Concentration Each NDC 0641-6262-01 Carton Containing 1 unit 100 mEq/50 mL (2 mEq/mL) NDC 0641-6262-01 Pharmacy Bulk Package NDC 0641-6263-10 Carton Containing 10 units 200 mEq/100 mL (2 mEq/mL) NDC 0641-6263-01 Pharmacy Bulk Package Store at 20 to 25oC (68 to 77oF). [See USP Controlled Room Temperature.]

Adverse event reports

Source: openFDA FAERS
64
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: SODIUM ACETATE ANHYDROUS. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0641-6261-01 0641-6261 Hikma Pharmaceuticals USA Inc. 1 VIAL in 1 CARTON (0641-6261-01) / 20 mL in 1 VIAL May 20, 2024
0641-6262-01 0641-6262 Hikma Pharmaceuticals USA Inc. 1 VIAL in 1 CARTON (0641-6262-01) / 50 mL in 1 VIAL May 20, 2024
0641-6263-10 0641-6263 Hikma Pharmaceuticals USA Inc. 10 VIAL in 1 CARTON (0641-6263-10) / 100 mL in 1 VIAL (0641-6263-01) May 20, 2024
0641-6261 0641-6261 Hikma Pharmaceuticals USA Inc. — May 20, 2024
0641-6262 0641-6262 Hikma Pharmaceuticals USA Inc. — May 20, 2024
0641-6263 0641-6263 Hikma Pharmaceuticals USA Inc. — May 20, 2024

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.